

LONG TERM OBJECTIVE

The Coronation Global Managed Strategy provides investors with access to the best investment ideas from around the world, with the aim of maximising long-term capital growth. It blends individual asset selection to reflect Coronation's view across asset classes, regions and currencies. The intent is to remain fully invested in foreign assets. The Strategy will hold its exposure to foreign assets in a variety of currencies, primarily the US dollar, British pound, euro and Japanese yen. The Strategy's objective is to outperform the global markets as measured by an equity-biased composite benchmark over a 5-year period.

INVESTMENT APPROACH

Coronation is a long-term, valuation-driven investment house. Our aim is to identify mispriced assets trading at discounts to their long-term business value (fair value) through extensive proprietary research. In calculating fair values, through our fundamental research, we focus on through-the-cycle normalised earnings and/or free cash flows using a long-term time horizon. The Portfolio is constructed on a cleanslate basis based on the relative risk-adjusted upside to fair value of each underlying security. The Portfolio is constructed with no reference to a benchmark. We do not equate risk with tracking error, or divergence from a benchmark, but rather with a permanent loss of capital.

STRATEGY RETURNS GROSS OF FEES

| Period | Strategy | Benchmark | Active Return |
|------------------------------|----------|-----------|---------------|
| Since Inception (cumulative) | 264.5% | 182.4% | 82.1% |
| Since Inception p.a. | 8.6% | 6.9% | 1.7% |
| Latest 15 years p.a. | 9.2% | 7.4% | 1.8% |
| Latest 10 years p.a. | 7.6% | 6.8% | 0.8% |
| Latest 5 years p.a. | 11.2% | 7.7% | 3.5% |
| Latest 3 years p.a. | 19.5% | 11.5% | 8.0% |
| Latest 1 year | 38.4% | 13.5% | 24.9% |
| Year to date | 21.4% | 9.1% | 12.3% |
| Month | 5.4% | 3.5% | 1.9% |

PERFORMANCE & RISK STATISTICS (Since inception)

| | Strategy | Benchmark |
|-------------------------------|----------|-----------|
| Annualised Standard Deviation | 13.3% | 10.0% |
| Maximum Drawdown | (26.5)% | (17.2)% |

ASSET ALLOCATION


| Asset Type | % Strategy |
|------------|------------|
| Equities | 69.6% |
| Bonds | 20.7% |
| Cash | 8.2% |
| Property | 1.5% |

GENERAL INFORMATION

| | |
|-------------------|--|
| Inception Date | 01 November 2009 |
| Strategy Size * | \$1.07 billion |
| Strategy Status | Open |
| Mandate Benchmark | 60% MSCI Daily TR Net All Country World USD (NDUEACWF Index) and 40% Bloomberg Global-Aggregate Total Return Index Value Unhedged USD (LEGATRUU) |
| Redemption Terms | An anti-dilution levy will be charged |
| Base Currency | USD |

*Strategy assets under management as at the most recent quarter end.

GROWTH OF US\$100M INVESTMENT



Benchmark: 60% MSCI Daily TR Net All Country World USD (NDUEACWF Index) and 40% Bloomberg Global-Aggregate Total Return Index Value Unhedged USD (LEGATRUU)

TOP 10 HOLDINGS

| Holding | % Strategy |
|---|------------|
| US TBILL 0.000% 240725 (USA) | 7.4% |
| AUTO1 GROUP SE (DEU) | 4.1% |
| OBL FIX 2.100% 120429 (DEU) | 2.7% |
| AMAZON.COM INC (USA) | 2.6% |
| TAIWAN SEMICONDUCTOR MANUFACTURING CO (TWN) | 2.3% |
| WARNER BROS DISCOVERY (USA) | 2.2% |
| ENTAIN PLC (GBR) | 2.2% |
| US TBILL 0.000% 021025 (USA) | 2.0% |
| AIRBUS SE (FRA) | 2.0% |
| ELEVANCE HEALTH INC (USA) | 2.0% |

| GEOGRAPHIC EXPOSURE | | | CURRENCY EXPOSURE | | |
|---------------------|--|------------|-------------------|--|------------|
| Region | | % Strategy | Currency | | % Strategy |
| North America | | 47.7% | USD | | 60.3% |
| Europe | | 34.1% | EUR | | 18.4% |
| Asia | | 10.1% | GBP | | 13.0% |
| CEEMEA | | 3.7% | TWD | | 2.3% |
| LATAM | | 3.5% | CHF | | 1.2% |
| Japan | | 0.7% | CNY | | 1.1% |
| Other | | 0.2% | Other | | 3.7% |

PORTFOLIO MANAGER



Neil Padoa - BEconSc, FFA, CFA

Neil is a portfolio manager and head of Global Developed Markets. He joined Coronation in May 2012 and has 16 years’ investment experience.

FUND MANAGER

Please contact Coronation for further information

Sean Morris

Lead Client Service Fund Manager

tel: +27 21 680 2021

email: smorris@coronation.com

REGULATORY DISCLOSURE AND DISCLAIMER

The Prospectus of Coronation Global Opportunities Fund and Fund KIID can be sourced on the following link: <https://www.coronation.com/en/institutional/strategy-information/literature/ucits-fund-library/umbrella-fund> and a Summary of Investor Rights can be sourced on the following link: <https://www.coronation.com/en/institutional/about-us/ucits-v-disclosure/>.

Coronation Investment Management International (Pty) Limited and Coronational International Limited, are appointed by Coronation Global Fund Managers (Ireland) Limited to provide investment management services to certain Irish domiciled funds. Both are investment advisers registered with the United States Securities and Exchange Commission ("SEC"). An investment adviser's registration with the SEC does not imply a certain level of skill or training. Additional information about Coronation Investment Management International (Pty) Limited and Coronation International Limited is also available on the SEC's website at <https://www.adviserinfo.sec.gov>. The information in this document has not been approved or verified by the SEC or by any state securities authority. Coronation Investment Management International (Pty) Limited is licensed and regulated by the Financial Sector Conduct Authority of South Africa. Coronation International Limited is authorized and regulated by the Financial Conduct Authority of the United Kingdom.

This material is for information only and does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase an investment in the Strategy, nor shall it or the fact of its distribution form the basis of, or be relied upon in connection with, any contract for investment in the Strategy. Any such offer shall only be made pursuant to the provision of further information/prospectus in relation to the Strategy. The Strategy is subject to management, administration and performance fees. Past performance is not necessarily a guide to future performance. Investors may not receive back the full amount invested and may suffer capital loss. Investments in the Strategy may not be readily realisable. Opinions expressed in this document may be changed without notice at any time after publication. Nothing in this document shall constitute advice on the merits of buying and selling an investment. All income, capital gains and other tax liabilities that may arise as a result of investing in the Strategy, remain that of the investor.

The volatility of the Benchmark represented in the growth chart above may be materially different from that of the Strategy. In addition, the holdings in the accounts comprising the Strategy may differ significantly from the securities that comprise the Benchmark. The Benchmark has not been selected to represent an appropriate benchmark to compare the Strategy's performance, but rather is disclosed to allow for comparison of the Strategy's performance to that of a well-known and widely recognized Benchmark.

The information contained herein is not approved for use by the public and must be read together with our [Disclaimer](#) that contains important information. If you are in possession of a physical copy of this document and you are unable to access our [Disclaimer](#) online, kindly contact us at cib@coronation.com and a copy will be sent to you via email.

REVIEW FOR THE QUARTER

The second quarter of 2025 (Q2) began with a tariff tantrum and was characterised by policy uncertainty, elevated volatility and US dollar weakness. Yet markets finished at all-time highs. There was little to distinguish performance across the main geographical regions over the quarter, with the S&P 500 Index slightly underperforming (by ~50 basis points [bps]) the MSCI All Country World Index's 11.5% return, and both the MSCI Emerging Markets and MSCI ex-US indices slightly outperforming (by ~50bps). Global bond performance was also strong, delivering 4.5% for the period. The Strategy's outperformance continued, with a gain of 18.1% in the quarter, which was well ahead of the benchmark's 8.8%. For the last twelve months, the Strategy has returned 38.4% compared to 13.6% for the benchmark.

At quarter-end, the Strategy was positioned as follows:

- 65% effective equity
- 6% in real assets (listed infrastructure and property)
- 3% in high-yield fixed income
- 5% in inflation-linked assets
- 13% in investment-grade fixed income instruments
- 8% in short-dated T-bills

The Emerging Market (EM) quartet of MercadoLibre, Coupang, NU Holdings (Nubank) and Sea Ltd (Sea) were amongst the top contributors for the quarter. As we have discussed previously, we consider these to be four of the most competitively advantaged businesses within the EM universe. These companies all possess the key attributes of a winning business, with leading and improving market positions, exceptional management teams alongside a culture of innovation, as well as being digital businesses on the right side of technological change. Each business has a strong multi-year growth outlook, supported by structural tailwinds, and will generate very attractive returns on invested capital at scale.

MercadoLibre, the leading ecommerce and fintech player in Latin America, reported excellent quarterly results in May with revenue up 37% and operating profit up 45% on a year-on-year (YoY) basis – a continuation of the strong profitable growth that we have come to expect from this company. MercadoLibre has an extremely strong competitive position thanks to its synergistic ecosystem that includes ecommerce, payments, and credit. We continue to be attracted to its long growth runway, with ecommerce and credit penetration remaining low in its geographies.

Coupang is the leading ecommerce platform in South Korea. Ecommerce penetration in its home market is already high, but Coupang has been a consistent share gainer, being the only company to invest in end-to-end logistics capabilities. In fact, its market share has tripled from 10% in 2019 to almost 30% today. In addition to profitable growth in its home market, the company also offers optionality post its Taiwan launch.

Nubank is the largest digital bank in Latin America with operations in Brazil, Mexico, and Colombia. In a region where customer service from traditional banks is notoriously exclusionary, inefficient, and expensive, Nubank has grown rapidly to serve well north of 100m customers today. But Nubank's market share in its key credit products remains very low, providing a strong structural growth opportunity as it upsells additional product into its existing large captive user base.

Sea is a leading Southeast Asian internet platform, with strong positions across ecommerce (Shopee), financial services (Monee), and gaming (Garena). Shopee, its ecommerce arm, continues to solidify its leadership position with over 50% market share in Southeast Asia, and is a strong challenger in Brazil. This fast growth in ecommerce has been complemented by meaningful margin improvements. Monee also delivered exceptional growth with revenue up 58% and EBIT margins reaching 29%, as Sea continues to scale its loan book. Sea is serving an extremely underbanked population, with a unique ecosystem advantage given the data and distribution reach provided by its ecommerce arm.

Our healthcare holdings, which span the life sciences, health insurance and healthcare equipment sectors, underperformed this quarter, largely due to growing uncertainty around potential regulatory changes in the US. The Trump administration has proposed cuts to healthcare programmes, including reductions to government and academic funding, as well as the FDA and Medicaid. They have also implemented tariffs that affect the cost of drugs and medical equipment manufactured abroad. More recently, President Trump signed an executive order aimed at reducing US drug prices, which are currently about three times higher than in other developed markets. Most pharmaceutical companies earn the bulk of their profits in the US, and therefore, this change is raising concerns about how future innovation will be funded. These regulatory developments are adding a cloud of uncertainty over R&D spending and capital investment across the healthcare sector.

We believe market reactions have overshot the likely impact of these potential changes. We remain confident in our selected healthcare holdings and believe they are well-positioned across global supply chains, customer bases, and/or product Strategy's to not only navigate these changes but also gain market share in the process.

Our fixed income positioning remains conservative. The Strategy's duration of three years is more than three years shorter than that of the index, with a yield to maturity (YTM) of 4.8%, which compares to the YTM on the global aggregate bond index of 3.5%. With credit spreads in both the investment grade and high yield markets at low levels, we believe now is not the time to be reaching for yield.

We wrote in the Q1 commentary: *"In early April, markets sold off heavily following the announcement of the Trump administration's tariff plan. A negative reaction is understandable, considering the opening gambit is far worse than initial expectations. The sell-off has, in our view, been indiscriminate, reflecting widespread fear and de-risking, as opposed to a rational reassessment of specific company fundamentals."*

For investors who allocate capital with a long-term horizon and who have a robust assessment of what a stock is worth, this volatility is an opportunity to be exploited.

We have followed our valuation discipline and responded to the changed opportunity set. This has caused Strategy turnover to be higher than usual, but the end result is a Strategy with a higher concentration of what we consider to be long-term winners, at more attractive valuations (and therefore higher expected future returns). We have also sold some short-dated US T-bills to fund a higher allocation to equities."

Markets have fully recovered from April's sell-off, and the upside of our equity holdings is now lower. As such, we have reduced equity exposure from the intra-quarter peak, reversing much of the asset allocation decisions made three months ago. Notably, the composition of the equity Strategy remains high quality, with c.90% of the equity bucket comprised of winning businesses.